Idorsia Competitors and Similar CompaniesClear all
Idorsia's competitors and similar companies include Novartis, Pfizer, Ipsen, Roche, Vifor Pharma, Roivant Sciences and Biocon.
 Idorsia Idorsia, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Ipsen Ipsen SA is a France-based pharmaceutical company that produces a range of various types of drugs. |  Roche Roche Holding is a biotech company that provides in-vitro diagnostics and supplies solutions across various disease areas. |  Vifor Pharma Vifor Pharma is a diversified group active throughout the healthcare market which, among other things, develops, manufactures, and markets pharmaceutical products. | |||
Founding Date | Founding Date 2017 | Founding Date 1996 | Founding Date 1849 | Founding Date 1929 | Founding Date 1896 | Founding Date 1927 | Founding Date 2014 | Founding Date 1978 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||
Locations | Locations Allschwil, CH HQ Shanghai, CN Lörrach, DE Chiyoda City, JP | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Bentley, AU Footscray, AU Mulgrave, AU Sydney, AU see more | Locations Boulogne-Billancourt, FR HQ Algiers, DZ South Yarra, AU Wien, AT Merelbeke, BE São Paulo, BR Mississauga, CA see more | Locations Glattbrugg, CH HQ Buenos Aires, AR Melbourne, AU Melbourne, AU Wien, AT Antwerpen, BE São Paulo, BR see more | Locations London, GB HQ Basel, CH Boston, US New York, US | Locations Bengaluru, IN HQ Bengaluru, IN Hyderabad, IN Visakhapatnam, IN Dublin, IE Kuala Lumpur, MY Puchong, MY see more | |
Employees | Employees 8007% increase | Employees 76,057 | Employees 83,0005% increase | Employees 5,325 | Employees 103,605 | Employees 2,200 | Employees 908 | Employees 16,315 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 163.9 b | Valuation ($) 10.2 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 8.8 b | Valuation ($) N/A |
Financial | ||||||||
Revenue (est.) | Revenue (est.) CHF152.4m (FY, 2023) | Revenue (est.) $54.1b (FY, 2023) | Revenue (est.) $58.5b (FY, 2023) | Revenue (est.) €3.1b (FY, 2023) | Revenue (est.) CHF58.7b (FY, 2023) | Revenue (est.) CHF1.8b (FY, 2021) | Revenue (est.) $124.8m (FY, 2023) | Revenue (est.) ₹142b (FY, 2024) |
Cost of goods | Cost of goods CHF7.2m (FY, 2023) | Cost of goods $8.2b (FY, 2023) | Cost of goods $25b (FY, 2023) | Cost of goods €449.1m (FY, 2023) | Cost of goods CHF12.4b (FY, 2023) | Cost of goods CHF498.7m (FY, 2021) | Cost of goods N/A | Cost of goods ₹50.9b (FY, 2024) |
Gross profit | Gross profit CHF146.4m (FY, 2023) | Gross profit $47.7b (FY, 2023) | Gross profit $33.5b (FY, 2023) | Gross profit €2.9b (FY, 2023) | Gross profit CHF48.5b (FY, 2023) | Gross profit CHF1.3b (FY, 2021) | Gross profit N/A | Gross profit ₹102b (FY, 2024) |
Net income | Net income (CHF297.9m) (FY, 2023) | Net income $9b (FY, 2023) | Net income $2.2b (FY, 2023) | Net income €652.6m (FY, 2023) | Net income CHF12.4b (FY, 2023) | Net income CHF265.4m (FY, 2021) | Net income $4.2b (FY, 2023) | Net income ₹13b (FY, 2024) |
Operating ⚠ | ||||||||
Patients | Patients N/A | Patients 10 m (FY, 2022) | Patients N/A | Patients N/A | Patients 22.8 m (FY, 2023) | Patients N/A | Patients N/A | Patients N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 27 (FY, 2021) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 4 (Q2, 2021) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 25 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 5 (Q2, 2021) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 27 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (Q2, 2021) | Phase III Trials Products N/A |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 10 (FY, 2021) | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 1 (Q2, 2021) | Registration Phase Products N/A |
Funding | ||||||||
Total funding raised | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 7.8b | Total funding raised N/A | Total funding raised $ 1.9b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Novartis
HQ
Basel, CH
Employees
76,057
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyPfizer
HQ
New York, US
Employees
83,000↑ 5% increase
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View companyIpsen
HQ
Boulogne-Billancourt, FR
Employees
5,325
Ipsen SA is a France-based pharmaceutical company that produces a range of various types of drugs.
View companyRoche
HQ
Basel, CH
Employees
103,605
Roche Holding is a biotech company that provides in-vitro diagnostics and supplies solutions across various disease areas.
View company